Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. [Review] (Record no. 4)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01918nam a22003497a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 221213s20182018 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2040-6207 |
| 024 ## - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1177_2040620718761778 [pii] |
| 024 ## - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1177/2040620718761778 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER | |
| Standard number or code | PMC5900827 [pmc] |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| PMID | 29713444 |
| 245 ## - TITLE STATEMENT | |
| Title | Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. [Review] |
| 251 ## - Source | |
| Source | Therapeutic Advances in Hematology. 9(5):109-121, 2018 May. |
| 252 ## - Abbreviated Source | |
| Abbreviated source | Ther Adv Hematol. 9(5):109-121, 2018 May. |
| 253 ## - Journal Name | |
| Journal name | Therapeutic advances in hematology |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Year | 2018 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Manufacturer | FY2018 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Publication date | 2018 May |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
| Publication status | ppublish |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
| Medline status | PubMed-not-MEDLINE |
| 266 ## - Date added to catalog | |
| Date added to catalog | 2022-12-13 |
| 520 ## - SUMMARY, ETC. | |
| Abstract | While the past decade has seen a revolution in understanding of the genetic and molecular etiology of the disease, in clinical practice, initial therapy for acute myeloid leukemia (AML) patients has been a relatively straightforward choice between intensive combination cytotoxic induction therapy as used for decades or less-intensive hypomethylating therapy. The year 2017, however, witnessed US Food and Drug Administration approvals of midostaurin, enasidenib, gemtuzumab ozogamicin and CPX-351 for AML patients, with many other promising agents currently in clinical trials. This review discusses these options, highlights unanswered questions regarding optimal combinations and proposes some suggested approaches for the personalization of initial therapy for AML patients. |
| 546 ## - LANGUAGE NOTE | |
| Language note | English |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME | |
| Institution | Washington Cancer Institute |
| 657 ## - INDEX TERM--FUNCTION | |
| Medline publication type | Journal Article |
| 657 ## - INDEX TERM--FUNCTION | |
| Medline publication type | Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Local Authors | DeStefano, Christin B |
| 790 ## - Authors | |
| All authors | DeStefano CB, Hourigan CS |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| DOI | <a href="https://dx.doi.org/10.1177/2040620718761778">https://dx.doi.org/10.1177/2040620718761778</a> |
| Public note | https://dx.doi.org/10.1177/2040620718761778 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | Journal Article |
| Item type description | Article |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedStar Authors Catalog | MedStar Authors Catalog | 12/13/2022 | 29713444 | 29713444 | 12/13/2022 | 12/13/2022 | Journal Article |